Freedom of Information Request: 0779 2020/21
University Hospitals Birmingham NHS Foundation Trust (UHB) completed a merger by acquisition of Heart of England NHS Foundation Trust (HEFT) on 1st April 2018. Due to historical differences in data collection/reporting across UHB and the former Heart of England NHS Foundation Trust this response has been provided by hospital site.
Dear University Hospital Birmingham NHS Foundation Trust,
I have a Freedom of Information request regarding Multiple Sclerosis. Could you kindly provide the answers to the questions mentioned below?
Queen Elizabeth Hospital Birmingham (QEHB):
- How many multiple sclerosis patients have been treated with these drugs in the past 6 months?
Ampyra (fampyra) – 0
Aubagio (teriflunomide) – 0
Avonex (interferon beta-1a) – 0
Betaferon (interferon beta-1b) – 0
Brabio (glatiramer acetate) – 0
Copaxone (glatiramer acetate) – 1
Extavia (beta interferon-1b) – 0
Gilenya (fingolimod) – 4
Lemtrada (alemtuzumab) – 1
Mavenclad (cladribine) – 0
Mayzent (siponimod) – 0
Ocrevus (ocrelizumab) – 1
Plegridy (peginterferon beta-1a) – 0
Rebif (beta interferon-1a) – 0
Tecfidera (dimethyl fumarate) – 0
Tysabri (natalizumab) – 4
Vumerity (diroximel fumarate) – 0
Zeposia (ozanimod) – 0
Zinbryta (daclizumab) – 0
- How many MS patients have been diagnosed with relapsing (RRMS), primary progressive (PPMS) or secondary progressive (SPMS) MS?
RRMS
PPMS
SPMS
Not known
509 – please note the medical code used for the conditions above is the same, therefore this figure includes all three diagnoses.
Heartlands, Good Hope and Solihull Hospitals (HGS):
- How many multiple sclerosis patients have been treated with these drugs in the past 6 months?
Please note – our systems do not allow us to identify multiple sclerosis patients only, the below data is for all patients regardless of diagnosis
Ampyra (fampyra) - 0
Aubagio (teriflunomide) – 0
Avonex (interferon beta-1a) – 0
Betaferon (interferon beta-1b) – 0
Brabio (glatiramer acetate) – 0
Copaxone (glatiramer acetate) – 0
Extavia (beta interferon-1b) – 0
Gilenya (fingolimod) – 0
Lemtrada (alemtuzumab) – 22
Mavenclad (cladribine) – 2
Mayzent (siponimod) – 0
Ocrevus (ocrelizumab) – 0
Plegridy (peginterferon beta-1a) – 0
Rebif (beta interferon-1a) – 0
Tecfidera (dimethyl fumarate) – 8
Tysabri (natalizumab) – 0
Vumerity (diroximel fumarate) – 0
Zeposia (ozanimod) – 0
Zinbryta (daclizumab) – 0
- How many MS patients have been diagnosed with relapsing (RRMS), primary progressive (PPMS) or secondary progressive (SPMS) MS?
RRMS
PPMS
SPMS
Not known
We do not hold this information, our systems cannot identify these patients.
